Viking Therapeutics (VKTX) Other financing activities (2015 - 2026)
Viking Therapeutics (VKTX) reported Other financing activities of $450000.0 for Q1 2026, up 50.0% on a YoY basis from $300000.0 in Q1 2025, and down 35.71% sequentially from $700000.0 in Q4 2025.
Viking Therapeutics (VKTX) Other financing activities (2015 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 6 years of Other financing activities data on file, last reported at $450000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities rose 50.0% year-over-year to $450000.0; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 66.08% YoY), and the FY2025 full-year result was $2.0 million, down 80.77% from the prior year.
- Other financing activities declined to $450000.0 in Q1 2026, from $700000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $4.4 million in Q1 2024 to a low of -$200000.0 in Q4 2023.
- A 4-year average of $1.5 million and a median of $600000.0 in 2024 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities soared 13057.89% in 2024 and sank 93.12% in 2025, its largest moves.
- Tracing VKTX's Other financing activities over 4 years: stood at -$200000.0 in 2023, then soared by 400.0% to $600000.0 in 2024, then climbed by 16.67% to $700000.0 in 2025, then plunged by 35.71% to $450000.0 in 2026.
- Business Quant data shows VKTX's Other financing activities at $450000.0 in Q1 2026, $700000.0 in Q4 2025, and $444000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 450,000.00 |
| Mar 31, 2026 | 450,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 444,000.00 |
| Sep 30, 2025 | 444,000.00 |
| Jun 30, 2025 | 556,000.00 |
| Jun 30, 2025 | 556,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 2.50 Mn |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.94 Mn |
| Jun 30, 2024 | 2.94 Mn |
| Mar 31, 2024 | 4.36 Mn |
| Mar 31, 2024 | 4.36 Mn |
| Dec 31, 2023 | -200,000.00 |
| Dec 31, 2023 | -200,000.00 |